The c.4004G>A variant in TECTA is a missense variant predicted to cause substitution of glycine by glutamic acid at amino acid 1335. The filtering allele frequency of this variant in gnomAD v4.1 is 0.2865% in the African/African American population, and there was agreement to apply BS1, which has a threshold of 0.3% for the ClinGen Hearing Loss group. The computational predictor REVEL gives a score of 0.35, which is neither above nor below the thresholds predicting a damaging or benign impact on TECTA function (BP4 and PP3 not met). The variant has been detected in heterozygosity in 1 individual with sloping moderately-severe sensorineural hearing loss, but no variant on the other allele was identified (Partners LMM internal data, SCV000711207.2). This variant has been observed in the heterozygous state and in combination with a second variant (phase unknown) in individuals undergoing testing for hearing loss (GeneDx internal data, SCV001770060.3). The variant has also been detected with another TECTA variant of uncertain significance in phase unknown in a patient with bilateral sensorineural hearing loss, and in the homozygous state in a patient with sensorineural hearing loss (Labcorp internal data, SCV001051355.5). In summary, this variant meets criteria to be classified as likely benign for autosomal recessive nonsyndromic hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: BS1 (ClinGen Hearing Loss VCEP specifications version 2; 5/21/2025).